G1 Therapeutics' GAAP loss for 9 months of 2022 was $113.91 million, up 5.2% from $108.33 million in the prior year. Revenue increased 59.9% to $41.051 million from $25.68 million a year earlier.
G1 Therapeutics' GAAP loss for 9 months of 2022 was $113.91 million, up 5.2% from $108.33 million in the prior year. Revenue increased 59.9% to $41.051 million from $25.68 million a year earlier. 
investor.g1therapeutics.com
English (US) 